TRC105
TRC105
TRC105 is a chimeric monoclonal antibody that targets CD105, also known as endoglin, a protein that is highly expressed on proliferating endothelial cells in the tumor vasculature. It is being investigated for its potential use in cancer therapy, particularly in combination with other anti-angiogenic agents.
Mechanism of Action[edit | edit source]
TRC105 binds to CD105, a component of the TGF-beta receptor complex, which is involved in angiogenesis, the process of new blood vessel formation. By targeting CD105, TRC105 inhibits angiogenesis, thereby reducing the blood supply to tumors and inhibiting their growth. This mechanism is particularly effective in tumors that are resistant to other forms of anti-angiogenic therapy.
Clinical Development[edit | edit source]
TRC105 has been evaluated in several clinical trials for various types of cancer, including renal cell carcinoma, hepatocellular carcinoma, and glioblastoma. It is often studied in combination with other therapies, such as bevacizumab, to enhance its anti-tumor effects.
Renal Cell Carcinoma[edit | edit source]
In renal cell carcinoma, TRC105 has been combined with axitinib, a tyrosine kinase inhibitor, in clinical trials. The combination aims to improve outcomes by targeting multiple pathways involved in tumor angiogenesis.
Hepatocellular Carcinoma[edit | edit source]
For hepatocellular carcinoma, TRC105 has been tested in combination with sorafenib, another tyrosine kinase inhibitor. This combination is based on the hypothesis that TRC105 can overcome resistance to sorafenib by targeting CD105.
Glioblastoma[edit | edit source]
In glioblastoma, TRC105 has been studied in combination with bevacizumab, an anti-VEGF antibody. The rationale is that while bevacizumab targets VEGF, TRC105 targets CD105, providing a dual blockade of angiogenic pathways.
Side Effects[edit | edit source]
The side effects of TRC105 are generally related to its mechanism of action and include fatigue, anemia, and thrombocytopenia. Some patients may experience infusion-related reactions, which are common with monoclonal antibody therapies.
Future Directions[edit | edit source]
Research is ongoing to determine the most effective combinations and dosing regimens for TRC105. There is also interest in exploring its use in other types of cancer and in combination with emerging therapies such as immune checkpoint inhibitors.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
